BACKGROUND: Patients with subarachnoid hemorrhage (SAH) frequently need a ventriculostomy for treatment of hydrocephalus. In some ICU practices, a ventriculostomy is considered a relative contraindication for subcutaneous heparin. We studied the risk of ventriculostomy-associated hemorrhage and deep venous thrombosis (DVT) in patients with anticoagulant prophylaxis. METHODS: This is a retrospective study of 241 consecutive patients with SAH and ventriculostomies treated at Mayo Clinic, Rochester from 2001 to 2014. DVT and pulmonary emboli (PE) prevention included subcutaneous or intravenous heparin, enoxaparin, dalteparin, and warfarin. The incidence of PE and DVT were noted within 30 days of hospital admission. Hemorrhages were classified as minor or major based on size and mass effect. RESULTS: Fifty-three (22 %) of the 241 patients were on prophylactic doses of anticoagulation while in the intensive care unit. Three of 53 patients on prophylactic anticoagulation had minor hemorrhages and none had major hemorrhages. Four (7.5 %) of 53 patients who received prophylactic anticoagulation versus 34 (18 %) of 188 patients who did not receive prophylactic anticoagulation developed DVT (p = 0.09). One of 10 patients on therapeutic anticoagulation had a major and fatal hemorrhage. CONCLUSION: In our cohort, the risk of VTE was reduced by more than half in patients receiving chemoprophylaxis. Ventriculostomy-associated hemorrhages were rare and minor. Anticoagulant thromboprophylaxis is mostly safe and required in aneurysmal SAH.
BACKGROUND:Patients with subarachnoid hemorrhage (SAH) frequently need a ventriculostomy for treatment of hydrocephalus. In some ICU practices, a ventriculostomy is considered a relative contraindication for subcutaneous heparin. We studied the risk of ventriculostomy-associated hemorrhage and deep venous thrombosis (DVT) in patients with anticoagulant prophylaxis. METHODS: This is a retrospective study of 241 consecutive patients with SAH and ventriculostomies treated at Mayo Clinic, Rochester from 2001 to 2014. DVT and pulmonary emboli (PE) prevention included subcutaneous or intravenous heparin, enoxaparin, dalteparin, and warfarin. The incidence of PE and DVT were noted within 30 days of hospital admission. Hemorrhages were classified as minor or major based on size and mass effect. RESULTS: Fifty-three (22 %) of the 241 patients were on prophylactic doses of anticoagulation while in the intensive care unit. Three of 53 patients on prophylactic anticoagulation had minor hemorrhages and none had major hemorrhages. Four (7.5 %) of 53 patients who received prophylactic anticoagulation versus 34 (18 %) of 188 patients who did not receive prophylactic anticoagulation developed DVT (p = 0.09). One of 10 patients on therapeutic anticoagulation had a major and fatal hemorrhage. CONCLUSION: In our cohort, the risk of VTE was reduced by more than half in patients receiving chemoprophylaxis. Ventriculostomy-associated hemorrhages were rare and minor. Anticoagulant thromboprophylaxis is mostly safe and required in aneurysmalSAH.
Authors: Varun R Kshettry; Benjamin P Rosenbaum; Andreea Seicean; Michael L Kelly; Nicholas K Schiltz; Robert J Weil Journal: J Clin Neurosci Date: 2013-10-13 Impact factor: 1.961
Authors: Michael N Diringer; Thomas P Bleck; J Claude Hemphill; David Menon; Lori Shutter; Paul Vespa; Nicolas Bruder; E Sander Connolly; Giuseppe Citerio; Daryl Gress; Daniel Hänggi; Brian L Hoh; Giuseppe Lanzino; Peter Le Roux; Alejandro Rabinstein; Erich Schmutzhard; Nino Stocchetti; Jose I Suarez; Miriam Treggiari; Ming-Yuan Tseng; Mervyn D I Vergouwen; Stefan Wolf; Gregory Zipfel Journal: Neurocrit Care Date: 2011-09 Impact factor: 3.210
Authors: David K Kung; Bruno A Policeni; Ana W Capuano; James D Rossen; Pascal M Jabbour; James C Torner; Matthew A Howard; David Hasan Journal: J Neurosurg Date: 2010-10-15 Impact factor: 5.115
Authors: Jack M Leschke; Andrew Lozen; Mayank Kaushal; Akinwunmi Oni-Orisan; Mazen Noufal; Osama Zaidat; Glen A Pollock; Wade M Mueller Journal: Neurocrit Care Date: 2017-08 Impact factor: 3.210
Authors: Juan José Yepes-Nuñez; Anita Rajasekhar; Maryam Rahman; Philipp Dahm; David R Anderson; Luis Enrique Colunga-Lozano; Stephanie Ross; Meha Bhatt; Kelly Estrada Orozco; Federico Popoff; Matthew Ventresca; Angela M Barbara; Sara Balduzzi; Housne Begum; Arnav Agarwal; Wojtek Wiercioch; Robby Nieuwlaat; Gian Paolo Morgano; Holger J Schünemann Journal: Blood Adv Date: 2020-06-23
Authors: Sang Hyuk Lee; Seung Hwan Kim; Ji Hwan Jang; Young Zoon Kim; Kyu Hong Kim; Taek Min Nam Journal: J Cerebrovasc Endovasc Neurosurg Date: 2022-09-06